ONWARD Medical, a neurotechnology company based in Eindhoven, Netherlands, has secured €40.6 million in funding to accelerate the development and commercialization of its innovative spinal cord stimulation (SCS) solutions. The company plans to use the capital to advance its pivotal trial for the Empower BP system, which aims to treat blood pressure instability in individuals with spinal cord injuries. The funding also supports the broader market rollout of its existing ARC-EX® external therapy system, which has already received regulatory clearance.
Advancing Spinal Cord Stimulation for Blood Pressure Management
The Empower BP trial is a crucial step in ONWARD Medical’s mission to address the complex health challenges faced by spinal cord injury patients. Blood pressure instability, a common and life-threatening complication, can severely impact quality of life and recovery outcomes. The company's ARC-IM® implantable system is designed to deliver targeted electrical stimulation to the spinal cord, potentially stabilizing blood pressure and reducing the risk of cardiovascular complications.
The funding round not only underscores investor confidence in ONWARD Medical's technology but also extends the company's cash runway into the first quarter of 2028. This financial cushion will allow the company to continue its clinical trials, regulatory submissions, and commercial expansion efforts. The company’s dual approach—developing both external and implantable systems—positions it as a comprehensive solution provider in the growing field of neuromodulation.
Expanding Access to Neurotechnology
With its ARC-EX® system already cleared for use, ONWARD Medical is now focused on scaling its reach and improving patient access to its therapeutic offerings. The company’s strategy reflects a broader trend in medical technology toward personalized, precision-based treatments that leverage advanced neurostimulation to manage chronic conditions.
As the field of neurotechnology continues to evolve, ONWARD Medical’s progress in spinal cord stimulation highlights the potential for medical devices to significantly improve patient outcomes. With its latest funding, the company is well-positioned to make a meaningful impact in the lives of individuals living with spinal cord injuries and related complications.
